CLL
Conference Coverage
Why CLL may go chemo free
NEW YORK – The approach to treating chronic lymphocytic leukemia is evolving, and while chemoimmunotherapy remains a reasonable initial option in...
From the Journals
AML leads percent gains in 5-year survival among leukemias
For 2008-2013, the 5-year relative survival rate for all leukemia was 60.1%, compared with 10% in 1950-1954.
Conference Coverage
Lenalidomide maintenance extended progression-free survival in high-risk CLL
SAN DIEGO - Lenalidomide maintenance may be an option for patients with chronic lymphocytic leukemia at risk of early progression.
Conference Coverage
Ibrutinib continues to wow in CLL/SLL
SAN DIEGO – More than 90% of the first patients with previously untreated chronic lymphocytic leukemia who received ibrutinib in an early study...
Conference Coverage
Lenalidomide improves PFS after 1st and 2nd line CLL therapy
SAN DIEGO – Lenalidomide, a mainstay of maintenance therapy for multiple myeloma, is now making inroads into maintenance therapy following first-...
Conference Coverage
Idelalisib held unlikely to become frontline therapy for CLL
Safety issues with idelalisib, a first-in-class PI3K delta inhibitor, are an important concern in patients with chronic lymphocytic leukemia–...
From the Journals
Targeted therapies predicted to blow out costs for CLL
Economic models indicate the annual cost in the United States of managing chronic lymphocytic leukemia will increase from its current level of $0....
From the Journals
Minimal residual disease status predicts 10-year survival in CLL
Patients who have chronic lymphocytic leukemia and achieve minimal residual disease negativity have a high probability of long-term progression-...
From the Journals
CD49d trumps novel recurrent mutations for predicting overall survival in CLL
CD49d was a strong predictor of overall survival in a cohort of 778 unselected patients with chronic lymphocytic leukemia.
News
Survival in CLL predicted by minimum residual disease
Key clinical point: Quantifying minimum residual disease significantly improved the accuracy of progression-free survival estimates in patients...
News
CLL: Genetic aberrations predict poor treatment response in elderly
Key clinical point: In elderly patients who have chronic lymphocytic leukemia and comorbidities, several genetic abnormalities predict a poor...